IL44779A - Antigen of chemically modified polypeptides, their production and pharmaceutical preparations containing them - Google Patents
Antigen of chemically modified polypeptides, their production and pharmaceutical preparations containing themInfo
- Publication number
- IL44779A IL44779A IL44779A IL4477974A IL44779A IL 44779 A IL44779 A IL 44779A IL 44779 A IL44779 A IL 44779A IL 4477974 A IL4477974 A IL 4477974A IL 44779 A IL44779 A IL 44779A
- Authority
- IL
- Israel
- Prior art keywords
- pro
- ser
- polypeptide
- antigen according
- hormone
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 96
- 102000036639 antigens Human genes 0.000 title claims abstract description 78
- 108091007433 antigens Proteins 0.000 title claims abstract description 78
- 239000000427 antigen Substances 0.000 title claims abstract description 73
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 92
- 229920001184 polypeptide Polymers 0.000 title claims description 89
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 238000004519 manufacturing process Methods 0.000 title description 4
- 229940088597 hormone Drugs 0.000 claims abstract description 79
- 239000005556 hormone Substances 0.000 claims abstract description 79
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims abstract description 18
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims abstract description 18
- 229940028334 follicle stimulating hormone Drugs 0.000 claims abstract description 18
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims abstract description 13
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims abstract description 13
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims abstract description 12
- 102000004576 Placental Lactogen Human genes 0.000 claims abstract description 10
- 108010003044 Placental Lactogen Proteins 0.000 claims abstract description 10
- 239000000381 Placental Lactogen Substances 0.000 claims abstract description 10
- 101000687438 Homo sapiens Prolactin Proteins 0.000 claims abstract description 5
- 238000002649 immunization Methods 0.000 claims description 46
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 27
- 241001504519 Papio ursinus Species 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 230000001850 reproductive effect Effects 0.000 claims description 20
- 241000894007 species Species 0.000 claims description 18
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 claims description 14
- 230000003054 hormonal effect Effects 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 claims description 12
- 230000035790 physiological processes and functions Effects 0.000 claims description 11
- 238000007385 chemical modification Methods 0.000 claims description 10
- 102400000921 Gastrin Human genes 0.000 claims description 9
- 108010052343 Gastrins Proteins 0.000 claims description 9
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 9
- 108010051696 Growth Hormone Proteins 0.000 claims description 8
- 102100038803 Somatotropin Human genes 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000000122 growth hormone Substances 0.000 claims description 8
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 7
- 102400000345 Angiotensin-2 Human genes 0.000 claims description 7
- 229950006323 angiotensin ii Drugs 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 102000013275 Somatomedins Human genes 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 210000005059 placental tissue Anatomy 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 229950000244 sulfanilic acid Drugs 0.000 claims description 6
- -1 soma- tomedifln Proteins 0.000 claims description 5
- 102000011923 Thyrotropin Human genes 0.000 claims description 4
- 108010061174 Thyrotropin Proteins 0.000 claims description 4
- 230000035558 fertility Effects 0.000 claims description 4
- 108010033949 polytyrosine Proteins 0.000 claims description 4
- ZKZNWRUUTQNYTH-UHFFFAOYSA-N 4-azidobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(N=[N+]=[N-])C=C1 ZKZNWRUUTQNYTH-UHFFFAOYSA-N 0.000 claims description 3
- 108060003199 Glucagon Proteins 0.000 claims description 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 3
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 3
- 108010086019 Secretin Proteins 0.000 claims description 3
- 102100037505 Secretin Human genes 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 3
- 229960004666 glucagon Drugs 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 229960001319 parathyroid hormone Drugs 0.000 claims description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims description 3
- 229960002101 secretin Drugs 0.000 claims description 3
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 3
- 229950002929 trinitrophenol Drugs 0.000 claims description 3
- 102000009843 Thyroglobulin Human genes 0.000 claims description 2
- 108010034949 Thyroglobulin Proteins 0.000 claims description 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 2
- 201000000052 gastrinoma Diseases 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 229960002175 thyroglobulin Drugs 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 claims 3
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 claims 2
- 210000004900 c-terminal fragment Anatomy 0.000 claims 2
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 claims 1
- 102400000321 Glucagon Human genes 0.000 claims 1
- CUTPSEKWUPZFLV-WISUUJSJSA-N Thr-Cys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(O)=O CUTPSEKWUPZFLV-WISUUJSJSA-N 0.000 claims 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 108010054442 polyalanine Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 5
- 241000282412 Homo Species 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001592 luteinising effect Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000016087 ovulation Effects 0.000 description 11
- 230000027758 ovulation cycle Effects 0.000 description 11
- 230000002485 urinary effect Effects 0.000 description 11
- 241000282520 Papio Species 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 9
- 102000006771 Gonadotropins Human genes 0.000 description 8
- 108010086677 Gonadotropins Proteins 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 239000002622 gonadotropin Substances 0.000 description 8
- 230000011599 ovarian follicle development Effects 0.000 description 8
- 239000000583 progesterone congener Substances 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 6
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 6
- 229960003399 estrone Drugs 0.000 description 6
- 230000029849 luteinization Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 230000001817 pituitary effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 4
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 229940040129 luteinizing hormone Drugs 0.000 description 4
- 210000004914 menses Anatomy 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 206010000210 abortion Diseases 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 229940094892 gonadotropins Drugs 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000000624 ovulatory effect Effects 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 230000002516 postimmunization Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 2
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 2
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 101000895818 Homo sapiens Chorionic somatomammotropin hormone 1 Proteins 0.000 description 2
- 101000956228 Homo sapiens Chorionic somatomammotropin hormone 2 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010024769 Local reaction Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000027272 reproductive process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HHEAXWKUWDVIHS-UHFFFAOYSA-N 3-sulfanyloxolane-2,5-dione Chemical compound SC1CC(=O)OC1=O HHEAXWKUWDVIHS-UHFFFAOYSA-N 0.000 description 1
- WWKFKRPMYMQRAZ-UHFFFAOYSA-N 6-aminopyridazine-3-sulfonic acid Chemical compound S(=O)(C1=NN=C(C=C1)N)(=O)O WWKFKRPMYMQRAZ-UHFFFAOYSA-N 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000013469 Placental Hormones Human genes 0.000 description 1
- 108010065857 Placental Hormones Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002281 placental hormone Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL50668A IL50668A (en) | 1974-05-07 | 1976-10-12 | Polypeptide hormone antigens for use in fertility control their production and pharmaceutical compositions containing them |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35789273A | 1973-05-07 | 1973-05-07 | |
| US40682173A | 1973-10-16 | 1973-10-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL44779A0 IL44779A0 (en) | 1974-07-31 |
| IL44779A true IL44779A (en) | 1977-10-31 |
Family
ID=26999834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL44779A IL44779A (en) | 1973-05-07 | 1974-05-07 | Antigen of chemically modified polypeptides, their production and pharmaceutical preparations containing them |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS623128B2 (pl) |
| AT (1) | AT356263B (pl) |
| AU (1) | AU524925B2 (pl) |
| CA (1) | CA1057742A (pl) |
| CH (1) | CH622426A5 (pl) |
| DD (1) | DD113919A5 (pl) |
| DE (1) | DE2421943A1 (pl) |
| FR (1) | FR2228477B1 (pl) |
| GB (1) | GB1473601A (pl) |
| HK (1) | HK41280A (pl) |
| IE (1) | IE42002B1 (pl) |
| IL (1) | IL44779A (pl) |
| MY (1) | MY8100128A (pl) |
| NL (1) | NL7406098A (pl) |
| NZ (1) | NZ174192A (pl) |
| PL (1) | PL97318B1 (pl) |
| SE (1) | SE7406096L (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526716A (en) * | 1981-11-20 | 1985-07-02 | The Ohio State University | Antigenic modification of polypeptides |
| CA1054937A (en) * | 1975-01-28 | 1979-05-22 | Gursaran P. Talwar | Antipregnancy vaccine |
| FR2319379A1 (fr) * | 1975-07-29 | 1977-02-25 | All India Inst Medical Scie | Vaccin contre la gravidite et procede de sa preparation |
| JPS55160725A (en) * | 1975-07-30 | 1980-12-13 | Paashiyado Taruwaa Gaasaran | Contraceptive vaccine and its manufacture |
| NZ182272A (en) * | 1975-10-14 | 1985-03-20 | Univ Ohio State | Modified polypeptides for the immunological control of fertility,and pharmaceutical compositions |
| JPS5294416A (en) * | 1976-01-24 | 1977-08-09 | Paashiyado Taruwaa Gaasaran | Vaccine for contraception and use of same |
| JPS5633907Y2 (pl) * | 1976-09-16 | 1981-08-11 | ||
| US4096237A (en) * | 1977-03-14 | 1978-06-20 | Hoffmann-La Roche Inc. | Immunoassay for β-endorphin |
| US4234561A (en) * | 1978-02-06 | 1980-11-18 | Research Corporation | Antigen for early pregnancy test and contraceptive vaccine |
| US4310455A (en) * | 1979-04-17 | 1982-01-12 | Research Corporation | Antigen for early pregnancy test and contraceptive vaccine |
| CA1239346A (en) * | 1985-06-04 | 1988-07-19 | Gursaran P. Talwar | Birth control vaccine |
| FR2832066A1 (fr) * | 2001-11-14 | 2003-05-16 | Agronomique Inst Nat Rech | Compositions vaccinales contraceptives comprenant un peptide ou un ensemble de peptides codes par tout ou partie de l'exon 1 d'un recepteur de la fsh |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA903671A (en) * | 1972-06-27 | J. Lewis Andrew | Soluble cancer antigens coupled to foreign proteins | |
| DE1467782A1 (de) * | 1963-07-17 | 1968-12-12 | Behringwerke Ag | Verfahren zur Herstellung von kuenstlichen Antigenen |
| US3317400A (en) * | 1964-11-23 | 1967-05-02 | Upjohn Co | Enzymatic modification of bovine growth hormone by proteolytic streptomycete cell extracts |
| GB1393965A (en) * | 1971-05-05 | 1975-05-14 | Ortho Pharma Corp | Vaccine and method for inducing infertility in a male animal |
-
1974
- 1974-05-03 CH CH604874A patent/CH622426A5/de not_active IP Right Cessation
- 1974-05-06 CA CA199,003A patent/CA1057742A/en not_active Expired
- 1974-05-07 DE DE2421943A patent/DE2421943A1/de active Granted
- 1974-05-07 DD DD178336A patent/DD113919A5/xx unknown
- 1974-05-07 SE SE7406096A patent/SE7406096L/xx unknown
- 1974-05-07 PL PL1974170881A patent/PL97318B1/pl unknown
- 1974-05-07 AT AT377074A patent/AT356263B/de not_active IP Right Cessation
- 1974-05-07 AU AU68695/74A patent/AU524925B2/en not_active Expired
- 1974-05-07 FR FR7415780A patent/FR2228477B1/fr not_active Expired
- 1974-05-07 GB GB2001874A patent/GB1473601A/en not_active Expired
- 1974-05-07 NL NL7406098A patent/NL7406098A/xx not_active Application Discontinuation
- 1974-05-07 JP JP49051079A patent/JPS623128B2/ja not_active Expired
- 1974-05-07 IE IE967/74A patent/IE42002B1/en unknown
- 1974-05-07 NZ NZ174192A patent/NZ174192A/en unknown
- 1974-05-07 IL IL44779A patent/IL44779A/en unknown
-
1980
- 1980-08-07 HK HK412/80A patent/HK41280A/xx unknown
-
1981
- 1981-12-30 MY MY128/81A patent/MY8100128A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE7406096L (sv) | 1975-01-31 |
| NL7406098A (pl) | 1974-11-11 |
| FR2228477A1 (pl) | 1974-12-06 |
| IL44779A0 (en) | 1974-07-31 |
| AU524925B2 (en) | 1982-10-14 |
| MY8100128A (en) | 1981-12-31 |
| JPS5069221A (pl) | 1975-06-10 |
| AT356263B (de) | 1980-04-25 |
| CA1057742A (en) | 1979-07-03 |
| HK41280A (en) | 1980-08-15 |
| IE42002L (en) | 1974-11-07 |
| FR2228477B1 (pl) | 1977-07-01 |
| NZ174192A (en) | 1985-02-28 |
| JPS623128B2 (pl) | 1987-01-23 |
| DD113919A5 (de) | 1975-07-05 |
| AU6869574A (en) | 1975-11-13 |
| IE42002B1 (en) | 1980-05-21 |
| PL97318B1 (pl) | 1978-02-28 |
| CH622426A5 (en) | 1981-04-15 |
| DE2421943C2 (pl) | 1989-10-26 |
| ATA377074A (de) | 1979-09-15 |
| DE2421943A1 (de) | 1974-11-28 |
| GB1473601A (en) | 1977-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4201770A (en) | Antigenic modification of polypeptides | |
| US4713366A (en) | Antigenic modification of polypeptides | |
| US4855285A (en) | Antigenic modification of polypeptides | |
| US4691006A (en) | Antigenic modification of polypeptides | |
| US4302386A (en) | Antigenic modification of polypeptides | |
| US4384995A (en) | Antigenic modification of polypeptides | |
| US4767842A (en) | Antigenic modification of polypeptides | |
| Chen et al. | Evidence for a gonadotropin from nonpregnant subjects that has physical, immunological, and biological similarities to human chorionic gonadotropin. | |
| US4161519A (en) | Process for preparing an antipregnancy vaccine | |
| US4526716A (en) | Antigenic modification of polypeptides | |
| US5006334A (en) | Antigenic modification of polypeptides | |
| IL44779A (en) | Antigen of chemically modified polypeptides, their production and pharmaceutical preparations containing them | |
| Matsuura et al. | Antibodies to the carboxyl-terminal fragment of human chorionic gonadotropin. beta.-subunit: characterization of antibody recognition sites using synthetic peptide analogs | |
| US5698201A (en) | Method for treatment of antigenically modified polypeptides | |
| US6096318A (en) | Antigenically modified HCG polypeptides | |
| US6217881B1 (en) | Antigenic modification of HCG polypeptides | |
| Tandon et al. | Efficacy of antibodies generated by Pr-β-hCG-TT to terminate pregnancy in baboons: Its reversibility and rescue by medroxyprogesterone acetate | |
| CA1085383A (en) | Antigenic modification of polypeptides | |
| Thanavala et al. | Affinity, cross-reactivity and biological effectiveness of rabbit antibodies against a synthetic 37 amino acid C-terminal peptide of human chorionic gonadotrophin. | |
| US6143305A (en) | Antigenically modified polypeptides composition | |
| Pala et al. | Immunization with hapten-coupled hCG-β subunit and its effect on the menstrual cycle | |
| Chen et al. | Limitations and problems of hCG-specific antisera | |
| US6039948A (en) | Method for treatment of antigenically modified polypeptides | |
| Thanavala et al. | Characterisation of the immunological response in marmoset monkeys immunised against hCG β-subunit and its relationship with their subsequent fertility | |
| EP1221964B1 (en) | Antigenic modification of polypeptides |